Polskie Radio checks the approval status of Lilly's retatrutide, which is still in trials. Thin on detail, so tap through for the specifics.
Recap by typeshit. Full story at www.polskieradio.pl.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Oasis reports failures including wrong compounds, low purity and off-label doses in BPC-157, semaglutide and Melanotan II, and says Peptide Gurus passed 9 of 46.
An investor take on Lilly's pipeline. One stat stands out: Lilly said 80% of Foundayo prescriptions went to people new to GLP-1 drugs.
Loading…